Bresagen rights issue cancelled
Wednesday, 02 March, 2005
Bresagen (ASX:BGN) has cancelled its non-renounceable rights issue which the company had hoped would raise AUD$8.8 million, citing failure to meet the minimum subscription of $2 million.
The company said its board had decided not to use a 90-day shortfall placement period open to directors, as the company's shares have recently been trading below the rights offer issue price of $0.095. All funds received will be returned to shareholders.
The company will instead access the convertible notes facility approved by shareholders in December. A shareholder meeting will be called in May to deal with this and related issues.
Bresagen was reinstated to the ASX in December after being in voluntary adminstration for almost a year following the failed spinout of the company's protein pharmaceuticals business.
The company was rescued by Queensland biotech CBio, which took a 51 per cent stake in the company, as well as funding the convertible notes facility, along with the Australian Technology Investment Fund.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
